ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG....

Click to view original post